Solid Biosciences Inc. SLDB SGT501 — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s sgt501 — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s SGT501 — research and development expense?
- Solid Biosciences Inc. (SLDB) reported SGT501 — research and development expense of $1.41M in Q1 2026.
- How has Solid Biosciences Inc.'s SGT501 — research and development expense changed year-over-year?
- Solid Biosciences Inc.'s SGT501 — research and development expense decreased by 68.5% year-over-year, from $4.47M to $1.41M.
- What is the long-term trend for Solid Biosciences Inc.'s SGT501 — research and development expense?
- Over 2 years (2023 to 2025), Solid Biosciences Inc.'s SGT501 — research and development expense has grown at a 73.6% compound annual growth rate (CAGR), from $3.2M to $9.64M.
- What does SGT501 — research and development expense mean?
- This metric represents the total costs incurred specifically for the research, clinical development, and manufacturing process optimization of the SGT501 gene therapy candidate. It captures the investment required to advance this specific therapeutic program through preclinical studies and clinical trials toward potential regulatory approval. Tracking this expense provides insight into the company's capital allocation strategy and the progress of its core pipeline assets.